ArticleEuropean urology2026
Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study.
Article in European urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- From Clinical Trials to Clinical Practice-Patterns of Practice Survey on Prostate SABR in Australia and New Zealand.Advances in radiation oncology · 2026Article
- Article
- Predictive Factors for Acute and Late Genitourinary and Gastrointestinal Toxicity Following Modern Radiotherapy for Prostate Cancer: A Narrative Review of Clinical, Dosimetric, Immunological, and Genetic Determinants.Life (Basel, Switzerland) · 2026Review
- Ultrahypofractionation of localized prostate cancer-an updated statement of the prostate cancer working group of the German Society of Radiation Oncology (DEGRO).Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Review
- Reirradiation of locally recurrent prostate Cancer: a review of prospective evidence and delineation and planning strategies from the reirradiation Collaborative group (ReCOG).Clinical and translational radiation oncology · 2026Review
- Intermediate rectal dose is associated with late toxicity after prostate SBRT: a dose-volume histogram principal component analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Diabetes Is an Independent Risk Factor for Radiation-Induced Hematuria After Robotic Stereotactic Body Radiotherapy for Prostate Cancer.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Baseline vulnerability over dosimetric precision: reframing late urinary toxicity after prostate stereotactic body radiotherapy.Translational andrology and urology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveStereotactic body radiotherapy (SBRT) is increasingly used for localised prostate cancer but is associated with higher urinary toxicity within 2 yr. This study identifies factors associated with late urinary toxicity after SBRT.
methodsPACE-B SBRT patients with dose-volume histogram data were analysed. All had low/intermediate-risk prostate cancer treated with SBRT alone (36.25 Gy per five fractions to planning target volume and 40 Gy per five fractions to clinical target volume). Doses to the surrogate/contoured urethra, bladder trigone, and bladder were extracted. Logistic regression identified factors associated with late toxicity. Outcomes of interest were Common Terminology Criteria for Adverse Events (CTCAE) grade 2+ urinary toxicity and International Prostate Symptom Score (IPSS; with imputation) +7 at 2 yr (a ≥7-point rise above baseline). KEY FINDINGS AND LIMITATIONS: Of 390 patients, 357 had 2-yr CTCAE data; 12% (n = 44) experienced grade 2+ urinary toxicity. Associated factors included higher baseline IPSS (odds ratio [OR] 1.11, 95% confidence interval or CI [1.05-1.18], p = 0.001), baseline urinary medication use (OR 2.32, 95% CI [1.09-4.95], p = 0.03), and grade 2+ acute urinary toxicity (OR 3.15, 95% CI [1.35-7.37], p = 0.008). Conventional LINAC (CL)-SBRT without fiducials and CyberKnife SBRT were associated with lower odds of grade 2+ urinary toxicity at 2 yr compared with CL-SBRT with fiducials; however, this association was not observed when using IPSS as the endpoint. No association was seen between urinary substructure dose and late toxicity. CONCLUSIONS AND CLINICAL IMPLICATIONS: Baseline urinary symptoms are associated with late urinary toxicity; patients with worse symptoms should be counselled on their elevated risk and consider moderate hypofractionation. The observed association between treatment technique and toxicity may reflect variations in urinary medication prescribing practices and warrants further validation.
Indexed as
Identifiers
41130825What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.